Bone Biologics Co. (NASDAQ:BBLG – Get Free Report)’s stock price traded down 2.4% during mid-day trading on Tuesday . The stock traded as low as $0.80 and last traded at $0.80. 24,534 shares were traded during mid-day trading, a decline of 98% from the average session volume of 1,407,702 shares. The stock had previously closed at $0.82.
Bone Biologics Price Performance
The business has a 50 day moving average price of $0.75 and a 200 day moving average price of $0.93.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.16. On average, research analysts predict that Bone Biologics Co. will post -5 EPS for the current fiscal year.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Recommended Stories
- Five stocks we like better than Bone Biologics
- Why Invest in 5G? How to Invest in 5G Stocks
- Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next
- Financial Services Stocks Investing
- Rocket Lab Expands Into Payloads: Should You Be Paying Attention?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
